Review





Similar Products

p63  (Akoya Biosciences)
97
Akoya Biosciences p63
P63, supplied by Akoya Biosciences, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/p63/product/Akoya Biosciences
Average 97 stars, based on 1 article reviews
p63 - by Bioz Stars, 2026-02
97/100 stars
  Buy from Supplier
p63  (Proteintech)
95
Proteintech p63
Antitumor activity of ROMV/TMAO and CD8 + T cells infiltration in ex vivo human LCO models. ( A ) Schematic depicting the process of construction of human lung cancer organoids (LCOs) from patient tumors for the subsequent CD8 + T cells infiltration and anti-tumor effect in LCOs after different treatment. ( B ) H&E staining images of human lung cancer tissues (LCTs) and derived organoids. Scale bars, 100 μm. ( C ) IF images of human LCTs and human LCOs. The LCOs kept the tumor cell organizations and the expression patterns of the characteristic markers (CK7, Napsin A and TTF1 for adenocarcinoma, CK5 and <t>P63</t> for squamous cell carcinoma) of LCTs. Red: markers. Blue: DAPI. Scale bars, 50 μm. ( D ) CD8 + T cells infiltration in human LCOs after different treatment. Red, anti-CD8α. Blue, DAPI. Scale bars, 40 μm. ( E to G ) Fluorescent images of LCOs from patient 100 (E), patient 102 (F) and patient 106 (G) showing the viability of organoids (green: live cells; red: dead cells) in LCOs + PBMC co-culture system after different treatment. Scale bars, 20 μm. The experiments are repeated three times. ( H ) Bright-field images of LCOs showing the size of organoids after different treatment. Scale bars, 100 μm. G1: PBS, G2: α-PD-L1, G3: ROMV/TMAO, G4: ROMV/TMAO + α-PD-L1.
P63, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/p63/product/Proteintech
Average 95 stars, based on 1 article reviews
p63 - by Bioz Stars, 2026-02
95/100 stars
  Buy from Supplier
il 17ra  (Biorbyt)
93
Biorbyt il 17ra
Antitumor activity of ROMV/TMAO and CD8 + T cells infiltration in ex vivo human LCO models. ( A ) Schematic depicting the process of construction of human lung cancer organoids (LCOs) from patient tumors for the subsequent CD8 + T cells infiltration and anti-tumor effect in LCOs after different treatment. ( B ) H&E staining images of human lung cancer tissues (LCTs) and derived organoids. Scale bars, 100 μm. ( C ) IF images of human LCTs and human LCOs. The LCOs kept the tumor cell organizations and the expression patterns of the characteristic markers (CK7, Napsin A and TTF1 for adenocarcinoma, CK5 and <t>P63</t> for squamous cell carcinoma) of LCTs. Red: markers. Blue: DAPI. Scale bars, 50 μm. ( D ) CD8 + T cells infiltration in human LCOs after different treatment. Red, anti-CD8α. Blue, DAPI. Scale bars, 40 μm. ( E to G ) Fluorescent images of LCOs from patient 100 (E), patient 102 (F) and patient 106 (G) showing the viability of organoids (green: live cells; red: dead cells) in LCOs + PBMC co-culture system after different treatment. Scale bars, 20 μm. The experiments are repeated three times. ( H ) Bright-field images of LCOs showing the size of organoids after different treatment. Scale bars, 100 μm. G1: PBS, G2: α-PD-L1, G3: ROMV/TMAO, G4: ROMV/TMAO + α-PD-L1.
Il 17ra, supplied by Biorbyt, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/il 17ra/product/Biorbyt
Average 93 stars, based on 1 article reviews
il 17ra - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier
il17 ra  (Biorbyt)
93
Biorbyt il17 ra
Antitumor activity of ROMV/TMAO and CD8 + T cells infiltration in ex vivo human LCO models. ( A ) Schematic depicting the process of construction of human lung cancer organoids (LCOs) from patient tumors for the subsequent CD8 + T cells infiltration and anti-tumor effect in LCOs after different treatment. ( B ) H&E staining images of human lung cancer tissues (LCTs) and derived organoids. Scale bars, 100 μm. ( C ) IF images of human LCTs and human LCOs. The LCOs kept the tumor cell organizations and the expression patterns of the characteristic markers (CK7, Napsin A and TTF1 for adenocarcinoma, CK5 and <t>P63</t> for squamous cell carcinoma) of LCTs. Red: markers. Blue: DAPI. Scale bars, 50 μm. ( D ) CD8 + T cells infiltration in human LCOs after different treatment. Red, anti-CD8α. Blue, DAPI. Scale bars, 40 μm. ( E to G ) Fluorescent images of LCOs from patient 100 (E), patient 102 (F) and patient 106 (G) showing the viability of organoids (green: live cells; red: dead cells) in LCOs + PBMC co-culture system after different treatment. Scale bars, 20 μm. The experiments are repeated three times. ( H ) Bright-field images of LCOs showing the size of organoids after different treatment. Scale bars, 100 μm. G1: PBS, G2: α-PD-L1, G3: ROMV/TMAO, G4: ROMV/TMAO + α-PD-L1.
Il17 Ra, supplied by Biorbyt, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/il17 ra/product/Biorbyt
Average 93 stars, based on 1 article reviews
il17 ra - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier
catalog no 12143 1 ap  (Proteintech)
95
Proteintech catalog no 12143 1 ap
Antitumor activity of ROMV/TMAO and CD8 + T cells infiltration in ex vivo human LCO models. ( A ) Schematic depicting the process of construction of human lung cancer organoids (LCOs) from patient tumors for the subsequent CD8 + T cells infiltration and anti-tumor effect in LCOs after different treatment. ( B ) H&E staining images of human lung cancer tissues (LCTs) and derived organoids. Scale bars, 100 μm. ( C ) IF images of human LCTs and human LCOs. The LCOs kept the tumor cell organizations and the expression patterns of the characteristic markers (CK7, Napsin A and TTF1 for adenocarcinoma, CK5 and <t>P63</t> for squamous cell carcinoma) of LCTs. Red: markers. Blue: DAPI. Scale bars, 50 μm. ( D ) CD8 + T cells infiltration in human LCOs after different treatment. Red, anti-CD8α. Blue, DAPI. Scale bars, 40 μm. ( E to G ) Fluorescent images of LCOs from patient 100 (E), patient 102 (F) and patient 106 (G) showing the viability of organoids (green: live cells; red: dead cells) in LCOs + PBMC co-culture system after different treatment. Scale bars, 20 μm. The experiments are repeated three times. ( H ) Bright-field images of LCOs showing the size of organoids after different treatment. Scale bars, 100 μm. G1: PBS, G2: α-PD-L1, G3: ROMV/TMAO, G4: ROMV/TMAO + α-PD-L1.
Catalog No 12143 1 Ap, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/catalog no 12143 1 ap/product/Proteintech
Average 95 stars, based on 1 article reviews
catalog no 12143 1 ap - by Bioz Stars, 2026-02
95/100 stars
  Buy from Supplier
trp63  (Proteintech)
95
Proteintech trp63
Antitumor activity of ROMV/TMAO and CD8 + T cells infiltration in ex vivo human LCO models. ( A ) Schematic depicting the process of construction of human lung cancer organoids (LCOs) from patient tumors for the subsequent CD8 + T cells infiltration and anti-tumor effect in LCOs after different treatment. ( B ) H&E staining images of human lung cancer tissues (LCTs) and derived organoids. Scale bars, 100 μm. ( C ) IF images of human LCTs and human LCOs. The LCOs kept the tumor cell organizations and the expression patterns of the characteristic markers (CK7, Napsin A and TTF1 for adenocarcinoma, CK5 and <t>P63</t> for squamous cell carcinoma) of LCTs. Red: markers. Blue: DAPI. Scale bars, 50 μm. ( D ) CD8 + T cells infiltration in human LCOs after different treatment. Red, anti-CD8α. Blue, DAPI. Scale bars, 40 μm. ( E to G ) Fluorescent images of LCOs from patient 100 (E), patient 102 (F) and patient 106 (G) showing the viability of organoids (green: live cells; red: dead cells) in LCOs + PBMC co-culture system after different treatment. Scale bars, 20 μm. The experiments are repeated three times. ( H ) Bright-field images of LCOs showing the size of organoids after different treatment. Scale bars, 100 μm. G1: PBS, G2: α-PD-L1, G3: ROMV/TMAO, G4: ROMV/TMAO + α-PD-L1.
Trp63, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/trp63/product/Proteintech
Average 95 stars, based on 1 article reviews
trp63 - by Bioz Stars, 2026-02
95/100 stars
  Buy from Supplier
p63 gene tex #gtx102425 antibody  (GeneTex)
90
GeneTex p63 gene tex #gtx102425 antibody
Antitumor activity of ROMV/TMAO and CD8 + T cells infiltration in ex vivo human LCO models. ( A ) Schematic depicting the process of construction of human lung cancer organoids (LCOs) from patient tumors for the subsequent CD8 + T cells infiltration and anti-tumor effect in LCOs after different treatment. ( B ) H&E staining images of human lung cancer tissues (LCTs) and derived organoids. Scale bars, 100 μm. ( C ) IF images of human LCTs and human LCOs. The LCOs kept the tumor cell organizations and the expression patterns of the characteristic markers (CK7, Napsin A and TTF1 for adenocarcinoma, CK5 and <t>P63</t> for squamous cell carcinoma) of LCTs. Red: markers. Blue: DAPI. Scale bars, 50 μm. ( D ) CD8 + T cells infiltration in human LCOs after different treatment. Red, anti-CD8α. Blue, DAPI. Scale bars, 40 μm. ( E to G ) Fluorescent images of LCOs from patient 100 (E), patient 102 (F) and patient 106 (G) showing the viability of organoids (green: live cells; red: dead cells) in LCOs + PBMC co-culture system after different treatment. Scale bars, 20 μm. The experiments are repeated three times. ( H ) Bright-field images of LCOs showing the size of organoids after different treatment. Scale bars, 100 μm. G1: PBS, G2: α-PD-L1, G3: ROMV/TMAO, G4: ROMV/TMAO + α-PD-L1.
P63 Gene Tex #Gtx102425 Antibody, supplied by GeneTex, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/p63 gene tex #gtx102425 antibody/product/GeneTex
Average 90 stars, based on 1 article reviews
p63 gene tex #gtx102425 antibody - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


Antitumor activity of ROMV/TMAO and CD8 + T cells infiltration in ex vivo human LCO models. ( A ) Schematic depicting the process of construction of human lung cancer organoids (LCOs) from patient tumors for the subsequent CD8 + T cells infiltration and anti-tumor effect in LCOs after different treatment. ( B ) H&E staining images of human lung cancer tissues (LCTs) and derived organoids. Scale bars, 100 μm. ( C ) IF images of human LCTs and human LCOs. The LCOs kept the tumor cell organizations and the expression patterns of the characteristic markers (CK7, Napsin A and TTF1 for adenocarcinoma, CK5 and P63 for squamous cell carcinoma) of LCTs. Red: markers. Blue: DAPI. Scale bars, 50 μm. ( D ) CD8 + T cells infiltration in human LCOs after different treatment. Red, anti-CD8α. Blue, DAPI. Scale bars, 40 μm. ( E to G ) Fluorescent images of LCOs from patient 100 (E), patient 102 (F) and patient 106 (G) showing the viability of organoids (green: live cells; red: dead cells) in LCOs + PBMC co-culture system after different treatment. Scale bars, 20 μm. The experiments are repeated three times. ( H ) Bright-field images of LCOs showing the size of organoids after different treatment. Scale bars, 100 μm. G1: PBS, G2: α-PD-L1, G3: ROMV/TMAO, G4: ROMV/TMAO + α-PD-L1.

Journal: Bioactive Materials

Article Title: Probiotic-inspired hybrid nanovesicles for enhancing immune checkpoint therapy efficiency via tumor immune microenvironment modulation

doi: 10.1016/j.bioactmat.2025.10.012

Figure Lengend Snippet: Antitumor activity of ROMV/TMAO and CD8 + T cells infiltration in ex vivo human LCO models. ( A ) Schematic depicting the process of construction of human lung cancer organoids (LCOs) from patient tumors for the subsequent CD8 + T cells infiltration and anti-tumor effect in LCOs after different treatment. ( B ) H&E staining images of human lung cancer tissues (LCTs) and derived organoids. Scale bars, 100 μm. ( C ) IF images of human LCTs and human LCOs. The LCOs kept the tumor cell organizations and the expression patterns of the characteristic markers (CK7, Napsin A and TTF1 for adenocarcinoma, CK5 and P63 for squamous cell carcinoma) of LCTs. Red: markers. Blue: DAPI. Scale bars, 50 μm. ( D ) CD8 + T cells infiltration in human LCOs after different treatment. Red, anti-CD8α. Blue, DAPI. Scale bars, 40 μm. ( E to G ) Fluorescent images of LCOs from patient 100 (E), patient 102 (F) and patient 106 (G) showing the viability of organoids (green: live cells; red: dead cells) in LCOs + PBMC co-culture system after different treatment. Scale bars, 20 μm. The experiments are repeated three times. ( H ) Bright-field images of LCOs showing the size of organoids after different treatment. Scale bars, 100 μm. G1: PBS, G2: α-PD-L1, G3: ROMV/TMAO, G4: ROMV/TMAO + α-PD-L1.

Article Snippet: The prepared sections were then stained with anti-CD8α (Abcam, ab237709), CK7 (Proteintech, 17513-1-AP), P63 (Proteintech, 12143-1-AP), Napsin A (ABclonal, A5594), CK5 (Proteintech, 28506-1-AP), and TTF1 (ABclonal, A18128).

Techniques: Activity Assay, Ex Vivo, Staining, Derivative Assay, Expressing, Co-Culture Assay